New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:38 EDTENTAEnanta Pharmaceuticals ABT-493 has potential, says JMP Securities
After examining data on Enanta's protease inhibitor, ABT-493. JMP Securities is encouraged by the drug's potential, as the firm thinks it can be competitive in the HCV space. The firm reiterates a $50 price target and Outperform rating on the shares.
News For ENTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
14:40 EDTENTAFDA approves Viekira Pak to treat hepatitis C
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use